Calbiotech Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Calbiotech's estimated annual revenue is currently $9.5M per year.(i)
  • Calbiotech's estimated revenue per employee is $238,450

Employee Data

  • Calbiotech has 40 Employees.(i)
  • Calbiotech grew their employee count by 29% last year.

Calbiotech's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP OperationsReveal Email/Phone
3
Regional VPReveal Email/Phone
4
Scientific DirectorReveal Email/Phone
5
lab tech.Reveal Email/Phone
6
ERP System AdministratorReveal Email/Phone
7
Assistant ELISA SupervisorReveal Email/Phone
8
ELISA supervisorReveal Email/Phone
9
Research ScientistReveal Email/Phone
10
Material Resource PlannerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M7920%N/AN/A
#2
$8.5M3111%N/AN/A
#3
$4.5M13-13%N/AN/A
#4
$8M25-4%N/AN/A
#5
$5.3M16-6%N/AN/A
#6
$54.2M163-8%N/AN/A
#7
$12M55-17%N/AN/A
#8
$10M30-9%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M43-7%N/AN/A
Add Company

What Is Calbiotech?

Calbiotech is a worldwide leader in immunoassay development and manufacturing. With over 30 years of experience, the Calbiotech team has established itself as a leader in the industry, offering over 200 products distributed to over 50 countries. Our investments in automation and state-of-the-art technologies help ensure our customers receive high-quality, stable, flexible, automation-ready, and cost effective products and services. Calbiotech's Custom Development team is ready to take your innovation from Pipeline to Productionâ„¢. We have custom developed hundreds of coated microplates, reagents, buffers and other components for pharmaceutical companies, universities and research centers in the U.S. and around the world.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$9.5M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.3M405%N/A
#2
$0.6M40344%N/A
#3
$8.3M41-2%N/A
#4
$10.7M4137%N/A
#5
$7.2M4628%N/A